Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
Acute Leukemia
Interventions
DRUG

PM01183 1 mg Powder for concentrate for solution for infusion and PM01183 4 mg Powder for concentrate for solution for infusion

"PM01183 Drug Product will be provided as a lyophilized powder for concentrate for solution for infusion with a strength of 1.0 mg/vial and 4.0 mg/vial.~Before use, the vials will be reconstituted with 2 ml or 8 ml of sterile water for injection to give a solution containing 0.5 mg/ml of PM01183."

Trial Locations (2)

55905

Rochester

77030

Houston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

PharmaMar

INDUSTRY

NCT01314599 - Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome | Biotech Hunter | Biotech Hunter